SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis

Huntington’s disease (HD), an incurable neurodegenerative disorder, has a complex pathogenesis including protein aggregation and the dysregulation of neuronal transcription and metabolism. Here, we demonstrate that inhibition of sirtuin 2 (SIRT2) achieves neuroprotection in cellular and invertebrate models of HD. Genetic or pharmacologic inhibition of SIRT2 in a striatal neuron model of HD resulted in gene expression changes including significant down-regulation of RNAs responsible for sterol biosynthesis. Whereas mutant huntingtin fragments increased sterols in neuronal cells, SIRT2 inhibition reduced sterol levels via decreased nuclear trafficking of SREBP-2. Importantly, manipulation of sterol biosynthesis at the transcriptional level mimicked SIRT2 inhibition, demonstrating that the metabolic effects of SIRT2 inhibition are sufficient to diminish mutant huntingtin toxicity. These data identify SIRT2 inhibition as a promising avenue for HD therapy and elucidate a unique mechanism of SIRT2-inhibitor-mediated neuroprotection. Furthermore, the ascertainment of SIRT2’s role in regulating cellular metabolism demonstrates a central function shared with other sirtuin proteins.

[1]  A. Kazantsev,et al.  Biological and Potential Therapeutic Roles of Sirtuin Deacetylases , 2008, Cellular and Molecular Life Sciences.

[2]  D. Russell,et al.  Knockout of the Cholesterol 24-Hydroxylase Gene in Mice Reveals a Brain-specific Mechanism of Cholesterol Turnover* , 2003, Journal of Biological Chemistry.

[3]  R. Kopito,et al.  HDAC6 and Microtubules Are Required for Autophagic Degradation of Aggregated Huntingtin* , 2005, Journal of Biological Chemistry.

[4]  E. Masliah,et al.  Statins reduce neuronal α‐synuclein aggregation in in vitro models of Parkinson’s disease , 2008, Journal of neurochemistry.

[5]  L. Guarente,et al.  Proteolipid Protein Is Required for Transport of Sirtuin 2 into CNS Myelin , 2007, The Journal of Neuroscience.

[6]  Ruth Luthi-Carter,et al.  Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice , 2003, The Journal of Neuroscience.

[7]  Fabrice P Cordelières,et al.  Histone Deacetylase 6 Inhibition Compensates for the Transport Deficit in Huntington's Disease by Increasing Tubulin Acetylation , 2007, The Journal of Neuroscience.

[8]  C. Kahn,et al.  SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. , 2007, Cell metabolism.

[9]  J. Olson,et al.  Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease , 2005, The Journal of Neuroscience.

[10]  R. Luthi-Carter.  Huntington's and other polyglutamine diseases: many effects of single gene mutations , 2007 .

[11]  James E Bear,et al.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Hersch,et al.  Drug targeting of dysregulated transcription in Huntington's disease , 2007, Progress in Neurobiology.

[13]  A. Colell,et al.  Mitochondrial Cholesterol Loading Exacerbates Amyloid β Peptide-Induced Inflammation and Neurotoxicity , 2009, The Journal of Neuroscience.

[14]  N. Déglon,et al.  Diminished hippocalcin expression in Huntington’s disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons , 2009, Journal of neurochemistry.

[15]  C. Mariotti,et al.  Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington’s disease , 2007, Neurobiology of Disease.

[16]  R. Albin,et al.  Neurological abnormalities in a knock-in mouse model of Huntington's disease. , 2001, Human molecular genetics.

[17]  W. Griffiths,et al.  The effect of 24S-hydroxycholesterol on cholesterol homeostasis in neurons: quantitative changes to the cortical neuron proteome. , 2008, Journal of proteome research.

[18]  H. Runne.  Transcriptional dysregulation in Huntington's disease , 2008 .

[19]  M. Tainsky,et al.  Microtubule Deacetylases, SirT2 and HDAC6, in the Nervous System , 2007, Neurochemical Research.

[20]  G. Barceló-Coblijn,et al.  Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice. , 2007, Journal of neurochemistry.

[21]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[22]  C. Benn,et al.  Huntingtin Modulates Transcription, Occupies Gene Promoters In Vivo, and Binds Directly to DNA in a Polyglutamine-Dependent Manner , 2008, The Journal of Neuroscience.

[23]  D. Housman,et al.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila , 2001, Nature.

[24]  M. Stefani,et al.  Cholesterol in Alzheimer's disease: unresolved questions. , 2009, Current Alzheimer research.

[25]  M. Hayden,et al.  Specific Loss of Brain ABCA1 Increases Brain Cholesterol Uptake and Influences Neuronal Structure and Function , 2009, The Journal of Neuroscience.

[26]  R. Abagyan,et al.  Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. , 2007, Science.

[27]  J. Denu,et al.  The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. , 2003, Molecular cell.

[28]  F. Alt,et al.  SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. , 2006, Genes & development.

[29]  S. Tabrizi,et al.  Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. , 2008, Brain : a journal of neurology.

[30]  C. Dotti,et al.  Cyp46-mediated cholesterol loss promotes survival in stressed hippocampal neurons , 2011, Neurobiology of Aging.

[31]  E. Verdin,et al.  Pesticides project progresses while the peace process stalls. , 1997, Environmental health perspectives.

[32]  D. Russell,et al.  Reduction of cholesterol synthesis in the mouse brain does not affect amyloid formation in Alzheimer's disease, but does extend lifespan , 2009, Proceedings of the National Academy of Sciences.

[33]  Vijay H Shah,et al.  Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo. , 2006, Human molecular genetics.

[34]  Bin Zhang,et al.  Sirtuin 2, a Mammalian Homolog of Yeast Silent Information Regulator-2 Longevity Regulator, Is an Oligodendroglial Protein That Decelerates Cell Differentiation through Deacetylating α-Tubulin , 2007, The Journal of Neuroscience.

[35]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[36]  I. Björkhem,et al.  Genetic connections between neurological disorders and cholesterol metabolism , 2010, Journal of Lipid Research.

[37]  G. Barceló-Coblijn,et al.  Brain neutral lipids mass is increased in α‐synuclein gene‐ablated mice , 2006 .

[38]  Ruben Abagyan,et al.  Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease , 2007, Science.

[39]  Christian Néri,et al.  Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons , 2005, Nature Genetics.

[40]  J. Olson,et al.  Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration , 2007, PLoS genetics.

[41]  A. Kenworthy,et al.  Molecular consequences of altered neuronal cholesterol biosynthesis , 2009, Journal of neuroscience research.

[42]  Leslie Michels Thompson,et al.  Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. , 2008, Human molecular genetics.

[43]  M. Hayden,et al.  Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. , 2007, Human molecular genetics.

[44]  M. Hennerici,et al.  Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  C. Bergmann,et al.  Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Q. Tong,et al.  SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction , 2007, Aging cell.